Plasma amyloid-beta oligomerization assay as a pre-screening test for amyloid status
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mofrad, Rosha Babapour | - |
dc.contributor.author | Scheltens, Philip | - |
dc.contributor.author | Kim, SangYun | - |
dc.contributor.author | Kang, Sungmin | - |
dc.contributor.author | Youn, Young Chul | - |
dc.contributor.author | An, Seong Soo A. | - |
dc.contributor.author | Tomassen, Jori | - |
dc.contributor.author | van Berckel, Bart N. M. | - |
dc.contributor.author | Visser, Pieter Jelle | - |
dc.contributor.author | van Der Flier, Wiesje M. | - |
dc.contributor.author | Teunissen, Charlotte E. | - |
dc.date.accessioned | 2021-08-05T02:40:47Z | - |
dc.date.available | 2021-08-05T02:40:47Z | - |
dc.date.created | 2021-08-05 | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1758-9193 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81830 | - |
dc.description.abstract | Objective: We assessed the performance of plasma amyloid oligomerization tendency (OA beta) as a marker for abnormal amyloid status. Additionally, we examined long-term storage effects on plasma OA beta. Methods: We included 399 subjects regardless of clinical diagnosis from the Amsterdam Dementia Cohort and European Medical Information Framework for AD project (age, 63.8 +/- 6.6; 44% female). Amyloid status was determined by visual read on positron emission tomography (PET; n(abnormal) = 206). Plasma OA beta was measured using the multimer detection system (MDS). Long-term storage effects on MDS-OA beta were assessed using general linear models. Associations between plasma MDS-OA beta and A beta-PET status were assessed using logistic regression and receiver operating characteristics analyses. Correlations between plasma MDS-OAP and CSF biomarker levels were evaluated using Pearson correlation analyses. Results: MDS-OA beta was higher in individuals with abnormal amyloid, and it identified abnormal A beta-PET with an area under the curve (AUC) of 0.74 (95% CI, 0.67-0.81), especially in samples with a storage duration < 4 years. Combining APOEe4 and age with plasma MDS-OA beta revealed an AUC of 81% for abnormal amyloid PET status (95% CI, 74-87%). Plasma MDS-OA beta correlated negatively with MMSE (r = - 0.29, p < .01) and CSF A beta 42 (r = - 0.20, p < 0.05) and positively with CSF Tau (r = 0.20, p = 0.01). Conclusions: Plasma MDS-OA beta combined with APOEe4 and age accurately identifies brain amyloidosis in a large A beta-confirmed population. Using plasma MDS-OA beta as a screener reduced the costs and number of PET scans needed to screen for amyloidosis, which is relevant for clinical trials. Additionally, plasma MDS-OA beta levels appeared affected by long-term storage duration, which could be of interest for others measuring plasma A beta biomarkers. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.relation.isPartOf | ALZHEIMERS RESEARCH & THERAPY | - |
dc.title | Plasma amyloid-beta oligomerization assay as a pre-screening test for amyloid status | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000677747400001 | - |
dc.identifier.doi | 10.1186/s13195-021-00873-w | - |
dc.identifier.bibliographicCitation | ALZHEIMERS RESEARCH & THERAPY, v.13, no.1 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85111307558 | - |
dc.citation.title | ALZHEIMERS RESEARCH & THERAPY | - |
dc.citation.volume | 13 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | An, Seong Soo A. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Blood-based biomarker | - |
dc.subject.keywordAuthor | Plasma A beta oligomer | - |
dc.subject.keywordAuthor | Amyloid status | - |
dc.subject.keywordAuthor | Multimer detection system | - |
dc.subject.keywordAuthor | Long-term storage | - |
dc.subject.keywordPlus | ALZHEIMERS-DISEASE | - |
dc.subject.keywordPlus | DIAGNOSTIC-CRITERIA | - |
dc.subject.keywordPlus | PROTEIN OLIGOMERS | - |
dc.subject.keywordPlus | DEMENTIA | - |
dc.subject.keywordPlus | BIOMARKER | - |
dc.subject.keywordPlus | PERFORMANCE | - |
dc.subject.keywordPlus | HYPOTHESIS | - |
dc.subject.keywordPlus | CONSENSUS | - |
dc.subject.keywordPlus | FLUID | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.